2020 ASCO Virtual Direct™ Highlights

 

2020 ASCO Virtual Direct™ Highlights
Avatar

2020 ASCO Update on AML: Is Anti-CD47 Antibody Magrolimab + Azacitidine Effective and Well Tolerated in TP53-mutant AML?

By 2020 ASCO Virtual Direct™ Highlights FEATURING Ravi Vij
By 2020 ASCO Virtual Direct™ Highlights FEATURING Ravi Vij
15 views
July 22, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

19:51
AstraZeneca Oncology

Management Strategies for Fatigue and Asthenia in First-line Mainten…

Feat. D. Czel, C. Arn

Featured Video

21:09
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam
Hematologic Oncology
08:30
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Lymphomas: Brentuximab Vedotin vs. Pembrolizumab…

Feat. N. Mehta-Shah
07:21
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Lymphomas: Should You Abandon ASCT in Patients W…

Feat. N. Mehta-Shah
08:25
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update: Zanubrutinib vs. Ibrutinib - Are Newer Generation …

Feat. N. Mehta-Shah
04:40
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on AML: Is Anti-CD47 Antibody Magrolimab + Azacitid…

Feat. R. Vij
07:54
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on AML: Are Ivosidenib and Enasidenib Good Options …

Feat. R. Vij
19:43
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Myeloma: KRd vs. VRd for Initial Therapy of Newl…

Feat. R. Vij